Alyssa Indart

Alyssa Indart serves as a Senior Consultant at Booz Allen Hamilton, specializing as a Technical SETA Contractor for ARPA-H Programs with a focus on immunology and gene editing since August 2024. Concurrently, Alyssa holds the position of Scientist at Weill Cornell Medicine, leading a project on NK cell phenotype regulators in triple-negative breast cancer. Previous experience includes an internship with Calico Life Sciences, where Alyssa contributed to enhancing anti-tumor responses in oncology, and doctoral studies at the University of California, San Francisco, culminating in a Ph.D. in Microbiology and Immunology, with research aimed at improving T Cell Therapy for Type 1 Diabetes. Notable achievements include a 2nd place win at the Merck Innovation Cup 2022, exploring immune dysregulation in autoimmune diseases and earlier roles at esteemed institutions such as NIH and Columbia University, where extensive research focused on autoimmune responses and DNA mutations in rare diseases.